Treatment of mice engrafted with wild-type JeKo-1 and single antigen expressing JeKo-1 with tandem, bicistronic, and monospecific CD79a and CD19 CAR T cells. (A-B) Cohorts of JeKo-1 tumor bearing NSG mice were treated with 0.6 × 10⁶ of mock-transduced T cells, CD19, tandem CD79a-19, bicistronic CD19-79a, or CD19 + CD79a CAR T cells (CD4:CD8 at 1:1 ratio). Data were pooled from 2 independent experiments consisting of a total of 6 to 12 mice per group. (A) Bioluminescent imaging of tumor bearing mice at indicated time points. Each line represents measurements in a single mouse. (B) Survival of mice in each treatment group. (C-D) IL-2 and IFN-γ production measured by ELISA of supernatants harvested 20 hours after coculture of CAR T cells on plate-bound CD79ab-Fc or (D) plate-bound CD19. Data given are means ± SEM from 3 independent experiments done with different donors. (E-F) Cohorts of NSG mice engrafted with JeKo-1^CD19− or JeKo-1^CD79− were either treated with 0.6 × 10⁶ of mock-transduced T cells, CD19, CD79a, tandem CD79a-19, or bicistronic CD19-79a CAR T cells (CD4:CD8 at 1:1 ratio). (E) Bioluminescent imaging of tumor bearing mice at indicated time points. Each line represents measurements in a single mouse. (F) Survival of mice in each treatment group. Data were pooled from 2 or 3 experiments with 7, 9, 11, or 12 mice per group. ∗∗∗P ≤ .001, ∗∗P ≤ .01 and ∗P ≤ .05, were calculated with panel B, and panel F Log-rank (Mantel-Cox) test, panels C-D, two-way ANOVA. Asterisks are color matched to the bispecific CAR to reflect the comparison between the indicated bispecific CAR and the monospecific CD79a CAR in panel C or CD19 CAR in panel D.